Halting the Oxford vaccine trial doesn't mean it's not safe- it shows they're following the right process
Due to a single event of an unexplained illness, the AstraZeneca Oxford group have announced a voluntary pause on all vaccinations across all sites of their COVID-19 vaccine candidate clinical trial. This pause will allow an independent committee to review the safety data and investigate the incident.
The following article, published in The Conversation, outlines how this halt doesn't necessarily indicate that the vaccine is not safe, but reflects the robust processes for clinical trials. It is important to recognise that whilst these clinical trials are moving at pandemic speed, safety is not being compromised.
2020年流感疫苗——现在接种还不算太晚
流感疾病可能在一年中的任何时间发生，建议 6 个月以上的每个人都接种疫苗。某些患者群体有资格获得国家免疫计划 (NIP) 资助的流感疫苗。不符合资助标准的人也可以购买。
有关 2020 年流感疫苗接种的更多信息，请参阅以下资源：
Australian Government Department of Health: 2020 influenza vaccines- it's not too late to get vaccinated
MVEC：流感疫苗建议
MVEC：流感疫苗 - 常见问题
Africa declared free of wild polio
After 4 years without a case of wild polio, the African region has been declared free of wild poliovirus. MVEC congratulates the efforts of everyone involved in accomplishing such a tremendous achievement which has been described by WHO director-general Dr Tedros Adhanom Ghebreyesus as "one of the greatest public health achievements of our time". This milestone means that Afghanistan and Pakistan are the only 2 countries worldwide who continue to see wild poliovirus transmission.
To read more on this remarkable effort please follow the links:
Africa kicks out wild polio
WHO: Global polio eradication initiative applauds WHO African region for wild polio-free certification
Zostavax safety advice: not to be administered to people with compromised immune function
The Therapeutic Goods Administration (TGA) have issued a reminder that Zostavax® vaccine should not be administered to people with compromised immune function. Vaccination in this patient group is contraindicated and can result in infection with the vaccine virus causing mild to severe complications (including death).
Further details on the alert can be seen here: TGA: Zostavax® vaccine
For more information on Zostavax® and access to the Zostavax® GP decision aid please review the MVEC pages below:
MVEC：带状疱疹
MVEC: Zoster vaccine (Zostavax®) FAQ's
The use of foetal tissue in vaccine development
There has been attention in the media recently regarding the use of foetal cell lines by the Oxford Vaccine Group to develop their COVID-19 vaccine candidate. Cell lines are currently used to manufacture many vaccines including varicella, hepatitis A, rabies and MMR vaccines.
The below information from the Children's Hospital of Philadelphia (CHoP) discusses the background behind using these cell lines in vaccine development as well as any potential ethical or religious concerns surrounding this.
Vaccine ingredients- Fetal tissues
The RCH Immunisation Service: Drive-through clinic is now open
To support families in continuing to receive scheduled vaccinations during the COVID-19 pandemic, the RCH Immunisation Service has just opened its own immunisation drive-through clinic. Additional precautions have been implemented to ensure the safety of all patients, families and staff. Access to medical care remains an essential service during this time and staying up to date with scheduled immunisations is encouraged.
The drive-through clinic will operate on Tuesdays and Wednesdays from 9am - 1pm until September 15.
Bookings for the drive-through clinic are mandatory and can be made by contacting the immunisation team via this link.
HealthEd podcast featuring Associate Professor Nigel Crawford
MVEC's Associate Professor Nigel Crawford was recently a guest speaker on the HealthEd podcast series Going Viral. In this podcast, Nigel discusses the COVID-19 vaccine, its access equity, safety and manufacture; as well as antibody responses following COVID-19 disease and how this may impact our vaccine strategy.
To listen to this podcast please follow the link
NDTV speak to Professor Kanta Subbarao, Director of WHO Collaborating Centre for Reference and Research on Influenza
有关 COVID-19 疫苗的问题与解答
这 疫苗教育中心 (VEC) 在 费城儿童医院 (CHoP) 最近推出了一个新的资源页面，回答与 COVID-19 疫苗的开发和安全性相关的常见问题。我们还鼓励读者将自己的问题直接提交给 VEC 团队以获得答复。
要访问此计划，请点击链接 这里
冠状病毒疫苗进展报告：竞标赢得 COVID-19 疫苗竞赛的项目
全球有超过 140 种候选疫苗处于不同的开发阶段，ABC 考察了澳大利亚研究人员在生产安全有效的 COVID-19 疫苗方面所发挥的作用。
ABC：冠状病毒疫苗进展：竞标赢得 COVID-19 疫苗竞赛的项目
要进一步探索 COVID-19 疫苗开发流程并听取国内外专家的意见，请订阅我们的播客系列：
COVID-19 疫苗之路